- Home
- PODC vs XAIR Comparison
PODC vs XAIR Comparison
Compare PODC & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- XAIR
- Stock Information
- Founded
- PODC 2013
- XAIR 2011
- Country
- PODC United States
- XAIR United States
- Employees
- PODC N/A
- XAIR N/A
- Industry
- PODC
- XAIR Medical/Dental Instruments
- Sector
- PODC
- XAIR Health Care
- Exchange
- PODC Nasdaq
- XAIR Nasdaq
- Market Cap
- PODC 29.7M
- XAIR 27.7M
- IPO Year
- PODC N/A
- XAIR N/A
- Fundamental
- Price
- PODC $2.01
- XAIR $0.35
- Analyst Decision
- PODC Strong Buy
- XAIR Strong Buy
- Analyst Count
- PODC 2
- XAIR 4
- Target Price
- PODC $4.75
- XAIR $3.67
- AVG Volume (30 Days)
- PODC 32.9K
- XAIR 1.5M
- Earning Date
- PODC 02-12-2025
- XAIR 02-10-2025
- Dividend Yield
- PODC N/A
- XAIR N/A
- EPS Growth
- PODC N/A
- XAIR N/A
- EPS
- PODC N/A
- XAIR N/A
- Revenue
- PODC $49,729,000.00
- XAIR $3,023,000.00
- Revenue This Year
- PODC $20.42
- XAIR $244.61
- Revenue Next Year
- PODC $19.38
- XAIR $258.76
- P/E Ratio
- PODC N/A
- XAIR N/A
- Revenue Growth
- PODC 22.98
- XAIR 338.75
- 52 Week Low
- PODC $1.10
- XAIR $0.30
- 52 Week High
- PODC $2.85
- XAIR $2.11
- Technical
- Relative Strength Index (RSI)
- PODC 42.53
- XAIR 41.74
- Support Level
- PODC $1.87
- XAIR $0.34
- Resistance Level
- PODC $2.30
- XAIR $0.40
- Average True Range (ATR)
- PODC 0.23
- XAIR 0.05
- MACD
- PODC -0.01
- XAIR -0.00
- Stochastic Oscillator
- PODC 30.00
- XAIR 10.21
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.